Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
AIMS: Elevated non-fasting triglycerides mark elevated levels of remnant cholesterol. Using a Mendelian randomization approach, we tested whether genetically increased remnant cholesterol in hypertriglyceridaemia due to genetic variation in the apolipoprotein A5 gene (APOA5) associates with an increased risk of myocardial infarction (MI). METHODS AND RESULTS: We resequenced the core promoter and coding regions of APOA5 in individuals with the lowest 1% (n = 95) and highest 2% (n = 190) triglyceride levels in the Copenhagen City Heart Study (CCHS, n = 10 391). Genetic variants which differed in frequency between the two extreme triglyceride groups (c.-1131T > C, S19W, and c.*31C > T; P-value: 0.06 to <0.001), thus suggesting an effect on triglyceride levels, were genotyped in the Copenhagen General Population Study (CGPS), the CCHS, and the Copenhagen Ischemic Heart Disease Study (CIHDS), comprising a total of 5705 MI cases and 54 408 controls. Genotype combinations of these common variants associated with increases in non-fasting triglycerides and calculated remnant cholesterol of, respectively, up to 68% (1.10 mmol/L) and 56% (0.40 mmol/L) (P < 0.001), and with a corresponding odds ratio for MI of 1.87 (95% confidence interval: 1.25-2.81). Using APOA5 genotypes in instrumental variable analysis, the observational hazard ratio for a doubling in non-fasting triglycerides was 1.57 (1.32-2.68) compared with a causal genetic odds ratio of 1.94 (1.40-1.85) (P for comparison = 0.28). For calculated remnant cholesterol, the corresponding values were 1.67(1.38-2.02) observational and 2.23(1.48-3.35) causal (P for comparison = 0.21). CONCLUSION: These data are consistent with a causal association between elevated levels of remnant cholesterol in hypertriglyceridaemia and an increased risk of MI. Limitations include that remnants were not measured directly, and that APOA5 genetic variants may influence other lipoprotein parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [62]
In the citing paper
“Epidemiological and Mendelian randomization studies have also pointed toward a causal role of elevated triglycerides in atherosclerosis due to an elevation of remnant cholesterol particles (7-9).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Elevated triglycerides are associated with an increase in remnant cholesterol, a decrease in high-density lipoprotein cholesterol (HDL-C), and an increase in LDL particles with a change in morphology to small, dense particles.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters [85,94-100].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [94]
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [76]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 1×
“Causal genetic estimates from instrumental variable analysis were compared with an observed risk of MI from observational epidemiology using the Altman and Bland method.(29)”
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Research works printed but not linked: 1
- 2001, Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 2835
Cited by
Items 201–300 of 506
Treatment of Hypertriglyceridemia: a Review of Current Options
Vrablík, M., & Češka, R. (2015) · Physiological Research · doi:10.33549/physiolres.933199 · Cited by 28
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 32
Bonfiglio, C., Leone, C. M., Silveira, L. V. D. A., Guerra, R., Misciagna, G., Caruso, M. G., Bruno, I., Buongiorno, C., Campanella, A., Guerra, V. M. B., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.002 · Cited by 24
Pintó, X., Masana, L., Civeira, F., Fernández‐Real, J. M., Ibarretxe, D., Candás‐Estébanez, B., Puzo, J., Díaz-Díaz, J. L., Amigó, N., Esteban, M., et al. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.04.004 · Cited by 28
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 25
Ren, Y., Pan, W., Li, X., Wang, S., Lv, H., Yao, Y. H., Wang, M., Xia, Y., & Yin, D. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10148-2 · Cited by 25
Prescription omega-3 fatty acid products: Considerations for patients with diabetes mellitus
Avallone, L., Shaikh, A., Hassan, A., & Tajuddin, N. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s97036 · Cited by 22
“78 Two additional ongoing studies are evaluating the effects of prescriptionstrength doses of OM3FAs on cardio vascular outcomes in patients at high risk for CVD. 79,80 While these trials are not focused on patients with diabetes per se, they will include patients with T2DM and the results will help establish whether…”
BackgroundNordestgaard, A. T., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf337 · Cited by 25
Self-citationAçıksarı, G., Çetinkal, G., Koçak, M., Atıcı, A., Celik, F. B., & Çalışkan, M. (2021) · International journal of cardiac imaging · doi:10.1007/s10554-021-02387-w · Cited by 22
Angiopoietin-like 3: An important protein in regulating lipoprotein levels
Burks, K. H., Basu, D., Goldberg, I. J., & Stitziel, N. O. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101688 · Cited by 23
Wang, J., Jin, R., Jin, X., Wu, Z., Zhang, H., Han, Z., Xu, Z., Liu, Y., Zhao, X., Guo, X., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029352 · Cited by 21
Epidemiology of cardiovascular disease: the new ESC Atlas and beyond
Lüscher, T. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy070 · Cited by 23
Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis
Miura, Y., & Suzuki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416224 · Cited by 22
Silbernagel, G., Chen, Y., Rief, M., Kleber, M. E., Hoffmann, M. M., Stojaković, T., Stang, A., Sarzynski, M. A., Bouchard, C., März, W., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad261 · Cited by 21
Remnant Cholesterol Is Associated With Gestational Diabetes Mellitus: A Cohort Study
Wang, W., Li, N., Wang, X., Zhang, X., Tu, M., Lin, L., Li, Q., Zhang, H., Liu, J., Yang, X., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad262 · Cited by 21
Remnant Cholesterol: The Leftovers and Their Contribution to Atherosclerotic Cardiovascular Disease
Bruemmer, D., & Cho, L. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.121.012615 · Cited by 21
Schuitema, P. C. E., Visseren, F. L. J., Nordestgaard, B. G., Teraa, M., van der Meer, M. G., Ruigrok, Y. M., Onland‐Moret, N. C., & Koopal, C. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120411 · Cited by 21
Self-citationChen, Y., Li, G., Guo, X., Ouyang, N., Li, Z., Ye, N., Yu, S., Yang, H., & Sun, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153388 · Cited by 22
The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction
Zhou, Y., Madsen, J. M., Özbek, B. T., Køber, L., Bang, L. E., Lønborg, J. T., & Engstrøm, T. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae102 · Cited by 20
Johansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101223 · Cited by 24
Self-citationCruz‐Bautista, I., Huerta‐Chagoya, A., Moreno-Macías, H., Rodríguez-Guillén, R., Ordóñez-Sánchez, M. L., Segura-Kato, Y., Mehta, R., Almeda‐Valdés, P., Gómez-Munguía, L., Chávez, X. R.-D., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01436-6 · Cited by 22
Zahger, D., Schwartz, G. G., Du, W., Szarek, M. J., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Jukema, J. W., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.035 · Cited by 22
Zhao, Q., Zhang, T., Cheng, Y., Ma, Y., Xu, Y.-K., Yang, J., & Zhou, Y.-J. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01355-y · Cited by 20
Pietri, P. G., Georgiopoulos, G., Tsiachris, D., Kordalis, A., Vlachopoulos, C. V., Vyssoulis, G. P., & Stefanadis, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-70237-1 · Cited by 20
Apolipoprotein A5, a unique modulator of fasting and postprandial triglycerides
Zhang, L., Liu, M., Black, D. D., & Tso, P. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159185 · Cited by 20
Delialis, D., Georgiopoulos, G. A., Aivalioti, E., Mavraganis, G., Dimopoulou, M., Sianis, A., Aggelidakis, L., Patras, R., Petropoulos, Ι., Ioannou, S., et al. (2022) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2022.05.011 · Cited by 20
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-56 · Cited by 23
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 21
Cui, C., Li, P., Qi, Y., Song, J., Han, T., Shang, X., Balmer, L. A., Sheng, C., Zha, Y., Xu, Z., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035764 · Cited by 20
Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes
Elías-López, D., Wadström, B. N., Vedel‐Krogh, S., Kobylecki, C. J., & Nordestgaard, B. G. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01555-1 · Cited by 18
Self-citationGenomic and transcriptomic predictors of triglyceride response to regular exercise
Sarzynski, M. A., Davidsen, P. K., Sung, Y. J., Hesselink, M. K. C., Schrauwen, P., Rice, T., Rao, D. C., Falciani, F., & Bouchard, C. (2015) · British Journal of Sports Medicine · doi:10.1136/bjsports-2015-095179 · Cited by 21
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 21
Triglycerides and Cardiovascular Outcomes—Can We REDUCE-IT ?
Pradhan, A. K., Bhandari, M., Vishwakarma, P., & Sethi, R. (2020) · International Journal of Angiology · doi:10.1055/s-0040-1701639 · Cited by 19
Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients
Wang, T., Xu, J., Fu, L., & Li, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13508 · Cited by 18
Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease?
Reiner, Ž. (2015) · Cardiology · doi:10.1159/000381304 · Cited by 18
Li, B., Zhou, X. J., Wang, W., Gao, Z., Yan, L., Qin, G., Tang, X., Wan, Q., Chen, L., Luo, Z., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13362 · Cited by 17
Elevated remnant cholesterol increase 6-year type 2 diabetes mellitus onset risk
Yuan, L., Liu, J., Huang, Z., Zhao, Y. W., Feng, Y., Yang, X., Hu, H., Zhang, J., Li, T.-Z., Li, Y., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117253 · Cited by 18
Remnant cholesterol traits and risk of stroke: A multivariable Mendelian randomization study
Wu, Z., Jiang, Y., Guo, Z., Li, P., Zheng, Y., Wang, Y., Zhang, H., Balmer, L. A., Li, X., Tao, L., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae033 · Cited by 18
Association Between Remnant Cholesterol and Risk of Hyperuricemia: A Cross-Sectional Study
Wang, Z., Wu, M., Yan, H., Zhong, S., Xu, R., Zhao, Z., & Yang, Q.-C. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2299-2914 · Cited by 17
A Comparison of Lipids and apoB in Asian Indians and Americans
Singh, K., Thanassoulis, G., Dufresne, L., Nguyen, A., Gupta, R., Narayan, K. M. V., Tandon, N., Sniderman, A. D., & Prabhakaran, D. (2021) · Global Heart · doi:10.5334/gh.882 · Cited by 17
Horace, R. W., Roberts, M. B., Shireman, T. I., Merhi, B. O., Jacques, P. F., Bostom, A. G., Liu, S., & Eaton, C. B. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab068 · Cited by 18
Chang, C., Lin, X.-R., Lin, Y.-L., Fang, W.-H., Lin, S., Chang, S., & Kao, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192740 · Cited by 17
Chen, S., Xu, Y., Chen, B., Lin, S., Lu, L., Cheng, M., Wang, Y., Yang, Q., Ling, S., Zhou, D., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02064-6 · Cited by 16
Hypertriglyceridemia and Multiorgan Disease Among U.S. Adults
Gurevitz, C., Chen, L., Muntner, P., & Rosenson, R. S. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100932 · Cited by 16
Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.191 · Cited by 17
Wang, J., Sun, Q., An, Y., Liu, J., Leng, S., & Wang, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951635 · Cited by 17
Chen, Y., Xu, C., Zhang, J., Zeng, C., Wang, X.-F., Zhou, R. L., Xu, L., Ao, Z., Lu, J., Shen, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201173 · Cited by 17
Costanzo, A. D., Perla, F. M., D’Erasmo, L., Arca, M., Chiesa, C., & Pacifico, L. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.01.019 · Cited by 17
Hvid, K., Balling, M., Afzal, S., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf203 · Cited by 15
Self-citationde Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 16
The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation
Anderson, J. L. C., Bakker, S. J. L., & Tietge, U. J. F. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.009 · Cited by 19
Targeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 16
Zhao, M., Xiao, M., Tan, Q., Ji, J., & Lu, F. Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-02000-0 · Cited by 15
Riesgo cardiovascular residual de origen lipídico. Componentes y aspectos fisiopatológicos
Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.007 · Cited by 17
Baum, S. J., & Scholz, K. P. (2019) · Clinical Cardiology · doi:10.1002/clc.23220 · Cited by 16
Kapoor, K., Alfaddagh, A., Stone, N. J., & Blumenthal, R. S. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.06.004 · Cited by 14
Song, Y., Zhao, Y. J., Bai, X., Cheng, W., Wang, L., Shu, M., Shu, Y., Zhang, L., & Jin, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111152 · Cited by 15
Zhong, L., Xie, B., Wang, H., & Ji, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-78610-0 · Cited by 15
Kamrani, F., Rezaee, A. M., Bigdeloo, L., Mojdehi, A. N., Darroudi, S., Talebkhah, M. H., Hadian, F., Hajian, A., Alizadeh, R., Alimi, H., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02627-1 · Cited by 15
Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Stefanutti, C., Labbadia, G., & Athyros, V. G. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140620120130 · Cited by 15
KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14
Liu, B., Fan, F., Zheng, B., Yang, Y., Jia, J., Sun, P., Jiang, Y., Li, K., Liu, J., Chen, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903390 · Cited by 15
Halalkhor, S., Jalali, F., Tilaki, K., & Shojaei, S. (2014) · Journal of Diabetes and Metabolic Disorders · doi:10.1186/2251-6581-13-48 · Cited by 15
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Pintó, X., Masana, L., Civeira, F., Fernández‐Real, J. M., Ibarretxe, D., Candás‐Estébanez, B., Puzo, J., Díaz-Díaz, J. L., Amigó, N., Esteban, M., et al. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.04.001 · Cited by 21
Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant Cholesterol
Masson, W. M., Lobo, M., Molinero, G., & Siniawski, D. A. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170069 · Cited by 17
Li, H., Cheng, B.-J., Yang, P., Wang, C., Ke, M., Li, T.-L., Wang, J., & Liu, R. (2024) · Toxics · doi:10.3390/toxics12060430 · Cited by 13
A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Wang, L., Zhang, Q., Wu, Z., & Huang, X. (2024) · Medicine · doi:10.1097/md.0000000000038754 · Cited by 17
Riis, J., Nordestgaard, B. G., & Afzal, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf092 · Cited by 15
Self-citationInfluence of the Human Lipidome on Epicardial Fat Volume in Mexican American Individuals
Leandro, A. C., Michael, L. F., Almeida, M., Kuokkanen, M., Huynh, K., Giles, C., Duong, T., Diego, V. P., Duggirala, R., Clarke, G. D., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889985 · Cited by 15
Using human genetics to predict the effects and side-effects of drugs
Stender, S., & Tybjærg‐Hansen, A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000280 · Cited by 13
Self-citationCase, B. C., Bress, A. P., Kolm, P., Philip, S., Herrick, J. S., Granowitz, C. B., Toth, P. P., Fan, W., Wong, N. D., HULL, M. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.004 · Cited by 14
Yang, R., Zhang, J., Yu, X., Yang, G., & Cai, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae001 · Cited by 12
Wu, S., Su, X., Zuo, Y., Chen, S., Tian, X., Xu, Q., Zhang, Y., Zhang, X., Wang, P., He, Y. L., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.05.008 · Cited by 12
Borén, J., Packard, C. J., Nordestgaard, B. G., & Catapano, A. L. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf214 · Cited by 12
Self-citationStraat, M. E., Martínez‐Téllez, B., Nahon, K. J., Janssen, L. G. M., Verhoeven, A., van der Zee, L., Mulder, M. T., Kooijman, S., Boon, M. R., van Lennep, J. E. R., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.04.004 · Cited by 12
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 13
Self-citationLauridsen, B. K., Stender, S., Frikke‐Schmidt, R., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx096 · Cited by 12
Self-citationPan, L., Jiang, W., Liao, L., Li, W., & Wang, F. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001320 · Cited by 11
Zhang, Y., Song, K., Bi, S., Li, M., & Yao, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1475933 · Cited by 11
Hipertrigliceridemia familiar/hipertrigliceridemia poligénica
Lahoz, C., & Mostaza, J. M. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.014 · Cited by 11
Ferchaud‐Roucher, V., Zaïr, Y., Aguesse, A., Krempf, M., & Ouguerram, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa459 · Cited by 13
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 12
Remnant cholesterol: a reliable prognostic marker?
Pirillo, A., & Catapano, A. L. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad107 · Cited by 13
Jia, Y.-P., Wang, J.-M., Lyu, J.-Q., Yang, H.-H., Miao, M.-Y., Wang, X., Wan, Z.-X., Zheng, Y., Qin, L.-Q., Li, F.-R., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100653 · Cited by 10
Ma, J., Xu, F., & Zhang, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-75951-8 · Cited by 10
Age dependent association between remnant cholesterol and cardiovascular disease
Wang, A., Tian, X., Zuo, Y., Chen, S., Meng, X., Chen, P., Li, H., Wu, S., & Wang, Y. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.09.004 · Cited by 10
Xu, X., Pan, T., Zhong, X., Du, Y., & Zhang, D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02449-1 · Cited by 10
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 11
Association between remnant cholesterol and the risk of cardiovascular disease in Chinese population
Jiang, X., Zhuang, J., Juan, Y., Zheng, X., & Zhang, H. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107825 · Cited by 10
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 10
Khounphinith, E., Yin, R., Cao, X., Huang, F., Wu, J., & Li, H. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.31729 · Cited by 10
Toth, P. P., Bays, H. E., Brown, W. V., Catapano, A. L., Davidson, M. H., Farnier, M., Tomassini, J. E., Jensen, E. H., Polis, A. B., & Tershakovec, A. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.09.001 · Cited by 10
Kang, M.-I., & Sung, J. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p119000226 · Cited by 11
Zhang, Y., Wu, S., Tian, X., Xu, Q., Xia, X., Zhang, X., Li, J., Chen, S., Liu, F., & Wang, A. (2024) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.05.002 · Cited by 9
Liu, Y., Skudder‐Hill, L., Kimita, W., Shamaitijiang, X., Sequeira, I. R., & Petrov, M. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16338 · Cited by 9
Schwere Hypertriglyzeridämie: Diagnostik und neue Therapieprinzipien
Kassner, U., Dippel, M., & Steinhagen‐Thiessen, E. (2017) · Der Internist · doi:10.1007/s00108-017-0234-z · Cited by 10
Yang, N., Wang, M., Liu, J., Liu, J., Hao, Y., Zhao, D., & on behalf of CCC-ACS Investigators (2022) · Metabolites · doi:10.3390/metabo12100898 · Cited by 9
Remnant Cholesterol and the Risk of Coronary Artery Disease in Patients With Type 2 Diabetes
Wang, K., Ding, Y., Wang, R., Yang, J., Liu, X., Han, H., Shen, H., Sun, Y., Zhou, Y., & Ge, H. (2022) · Angiology · doi:10.1177/00033197221121008 · Cited by 11
Colesterol-no HDL como objetivo terapéutico
Brea, Á., Hernández‐Mijares, A., Millán, J., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.07.002 · Cited by 11
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 34
- Issue
- 24
- Pages
- 1826-1833
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2040770080
- Cited by
- 501
- References
- 60
- Citations by year
- 2026: 28 · 2025: 53 · 2024: 48 · 2023: 40 · 2022: 51 · 2021: 45 · 2020: 41 · 2019: 39 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 30 · 2014: 20 · 2013: 11
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- remnant cholesterol, hypertriglyceridemia, myocardial infarction, APOA5, genetic variants, causal risk factors, remnant lipoproteins, Copenhagen City Heart Study, Copenhagen General Population Study, instrumental variables, Mendelian randomization
- MeSH terms
- Apolipoprotein A-V, Adult, Aged, Aged, 80 and over, Apolipoproteins A, Cholesterol, Female, Genotype, Humans, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Promoter Regions, Genetic, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Linkage Disequilibrium, Case-Control Studies, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.